Showing results (131-140 of 276) with videos related to

Sort By:
Pageof 28
Clinical Lymphoma, Myeloma & Leukemia|May 18, 2011
(90)Y ibritumomab tiuxetan (Zevalin) combined with BEAM (Z -BEAM) conditioning regimen plus autologous stem cell transplantation in relapsed or refractory low-grade CD20-positive B-cell lymphoma. A GELA phase II prospective studyDidier Decaudin, Nicolas Mounier, Hervé Tilly, et al.
BMC Cancer|June 15, 2014
RITA (Reactivating p53 and Inducing Tumor Apoptosis) is efficient against TP53abnormal myeloma cells independently of the p53 pathwaySylvanie Surget, Géraldine Descamps, Carole Brosseau, et al.
Blood|August 21, 2004
Combination of the mTOR inhibitor rapamycin and CC-5013 has synergistic activity in multiple myelomaNoopur Raje, Shaji Kumar, Teru Hideshima, et al.
Leukemia & Lymphoma|January 4, 2012
Efficacy of lenalidomide plus dexamethasone in patients older than 75 years with relapsed multiple myelomaCyrille Touzeau, Nicolas Blin, Aline Clavert, et al.
International Journal of Laboratory Hematology|August 26, 2023
Factors determining whether diffuse large B-cell lymphoma samples are detected by flow cytometryDavid Peng, Aruna Kodituwakku, Steven Le, et al.
The Journal of Antimicrobial Chemotherapy|June 24, 2022
Safety and risk of febrile recurrence after early antibiotic discontinuation in high-risk neutropenic patients with haematological malignancies: a multicentre observational studyRaphael Paret, Amandine Le Bourgeois, Gaëlle Guillerm, et al.
Neuroscience and Biobehavioral Reviews|July 6, 2022
Visual electrophysiology and neuropsychology in bipolar disorders: A review on current state and perspectivesKatelyne Tursini, Steven Le Cam, Raymund Schwan, et al.
Bulletin Du Cancer|January 11, 2021
[Eligibility of patients for CAR T-cell: Expert opinion-based collaborative work by the SFGM-TC]David Beauvais, Emmanuel Bachy, André Baruchel, et al.
Leukemia & Lymphoma|January 20, 2022
A phase-II study of atezolizumab in combination with obinutuzumab or rituximab for relapsed or refractory mantle cell or marginal zone lymphoma or Waldenström's macroglobulinemiaPanayiotis Panayiotidis, Gayane Tumyan, Catherine Thieblemont, et al.
Blood|October 5, 2016
Rational targeted therapies to overcome microenvironment-dependent expansion of mantle cell lymphomaDavid Chiron, Céline Bellanger, Antonin Papin, et al.
Pageof 28